1626 related articles for article (PubMed ID: 16123091)
21. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome.
Guzelmeric K; Alkan N; Pirimoglu M; Unal O; Turan C
Gynecol Endocrinol; 2007 Sep; 23(9):505-10. PubMed ID: 17852421
[TBL] [Abstract][Full Text] [Related]
22. [Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome].
Liu ZA; Xue YM; Chen LX; Cai Q; Chen H; Zhang J; Cui QH; Ge J; Yuan T
Zhonghua Fu Chan Ke Za Zhi; 2004 Sep; 39(9):586-90. PubMed ID: 15498183
[TBL] [Abstract][Full Text] [Related]
23. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Piperi C; Kalofoutis A; Creatsas G
Clin Endocrinol (Oxf); 2005 Jan; 62(1):37-43. PubMed ID: 15638868
[TBL] [Abstract][Full Text] [Related]
24. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
25. Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome.
Vrbíková J; Bicíková M; Tallová J; Hill M; Stárka L
Exp Clin Endocrinol Diabetes; 2002 Apr; 110(2):74-6. PubMed ID: 11928069
[TBL] [Abstract][Full Text] [Related]
26. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
[TBL] [Abstract][Full Text] [Related]
27. Effects of metformin treatment in women with polycystic ovary syndrome depends on insulin resistance.
Nawrocka J; Starczewski A
Gynecol Endocrinol; 2007 Apr; 23(4):231-7. PubMed ID: 17505944
[TBL] [Abstract][Full Text] [Related]
28. Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome.
Ziaee A; Oveisi S; Abedini A; Hashemipour S; Karimzadeh T; Ghorbani A
Acta Med Indones; 2012 Jan; 44(1):16-22. PubMed ID: 22451180
[TBL] [Abstract][Full Text] [Related]
29. Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Alexandraki K; Piperi C; Aessopos A; Paterakis T; Katsikis I; Panidis D
Metabolism; 2007 Jan; 56(1):129-34. PubMed ID: 17161235
[TBL] [Abstract][Full Text] [Related]
30. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
Kadoglou NP; Tsanikidis H; Kapelouzou A; Vrabas I; Vitta I; Karayannacos PE; Liapis CD; Sailer N
Metabolism; 2010 Mar; 59(3):373-9. PubMed ID: 19815243
[TBL] [Abstract][Full Text] [Related]
31. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.
Kriplani A; Agarwal N
J Reprod Med; 2004 May; 49(5):361-7. PubMed ID: 15214709
[TBL] [Abstract][Full Text] [Related]
32. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Fruzzetti F; Perini D; Lazzarini V; Parrini D; Gambacciani M; Genazzani AR
Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
[TBL] [Abstract][Full Text] [Related]
33. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin.
Maciel GA; Soares Júnior JM; Alves da Motta EL; Abi Haidar M; de Lima GR; Baracat EC
Fertil Steril; 2004 Feb; 81(2):355-60. PubMed ID: 14967373
[TBL] [Abstract][Full Text] [Related]
34. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance.
Lemay A; Dodin S; Turcot L; Déchêne F; Forest JC
Hum Reprod; 2006 Jan; 21(1):121-8. PubMed ID: 16199428
[TBL] [Abstract][Full Text] [Related]
35. [Exploration of the classification of polycystic ovarian syndrome].
Lin JF; Li X; Zhu MW
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
[TBL] [Abstract][Full Text] [Related]
36. An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet.
Glueck CJ; Goldenberg N; Sieve L; Wang P
Metabolism; 2008 Jul; 57(7):954-60. PubMed ID: 18555837
[TBL] [Abstract][Full Text] [Related]
37. Adiponectin and resistin serum levels in women with polycystic ovary syndrome during oral glucose tolerance test: a significant reciprocal correlation between adiponectin and resistin independent of insulin resistance indices.
Lewandowski KC; Szosland K; O'Callaghan C; Tan BK; Randeva HS; Lewinski A
Mol Genet Metab; 2005 May; 85(1):61-9. PubMed ID: 15862282
[TBL] [Abstract][Full Text] [Related]
38. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study.
Singh S; Akhtar N; Ahmad J
Diabetes Metab Syndr; 2012; 6(4):207-11. PubMed ID: 23199540
[TBL] [Abstract][Full Text] [Related]
39. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N
Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
[TBL] [Abstract][Full Text] [Related]
40. Serum leptin levels correlate with clinical and biochemical indices of insulin resistance in women with polycystic ovary syndrome.
Pehlivanov B; Mitkov M
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):153-9. PubMed ID: 19340711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
